CSL stock

CSL · ASX · AUD

$202.52Change from previous close: −0.20%Absolute change: −$0.40

Close · November 16, 2026

Price history

+12.24% over the period

1 year: from $180.44 (November 17, 2025) to $202.52 (November 16, 2026), +12.24%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$202.52
October 30, 2026$200.73
September 30, 2026$184.22
August 31, 2026$171.57
July 31, 2026$123.06
June 30, 2026$114.74
May 29, 2026$96.61
April 30, 2026$124.37
March 31, 2026$140.78
February 27, 2026$146.76
January 30, 2026$181.42
December 31, 2025$172.65
November 28, 2025$186.30
November 17, 2025$180.44

At a glance

  • The company

    Research, develops and distributes biopharmaceutical products and vaccines through CSL Behring, CSL Seqirus and CSL Vifor divisions

  • Latest results

    Quarter to June 30, 2025 · EPS $2.04 (estimate $2.70)

TickerLandia's take on CSL

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$90.00
52-wk high$205.48

−1.44% from the 52-week high

Analysts · 17 analysts

Average target$198.57−1.95% vs. price

Buy 9 · Hold 7 · Sell 1 · Buy

TickerLandia Fingerprint: CSL

Compared with similar companies: very strong momentum, very low growth, and very high dividend.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

CSL is cheaper than similar companies

CSL's Forward P/E: 21.4, −30% against the median of a group of 11 similar companies (30.4).

Compared with 11 similar companies

CSL's metrics compared with similar companies
MetricCSLPosition in the groupBand
Forward P/E21.4Low
Operating margin26.8%Middle
ROE-15.8%Low
Debt/equity0.67High
Price/book4.59Middle

Grey band: the middle half of the group; tick: the median; dot: CSL. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$7.47B

Latest quarter · Q2 2026

Net income

-$2.98B

Latest quarter · Q2 2026

Quarterly net margin

-39.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$96.75B
EPS
-$7.90
Volume
156.42K
Daily trading
€118.28M
Dividend yield
2.00%
Last ex-dividend on September 9, 2026

How CSL is changing

All results
  • Revenue grew 8.9% a year on average over the last 5 years

  • Operating margin rose from 25.7% to 26.8%

  • Shares outstanding up 5.7% in 5 years

Returns

CSL returns with dividends

$1,000 invested in CSL 5 years ago, on November 16, 2021, would be worth $716 today with dividends reinvested: −28.40% in total, −6.46% per year. On price alone it would be $659 (−34.12%).

PeriodCSLS&P/ASX 200$1,000 becomes
1 month+5.37%+3.40%$1,054
6 months+106.74%+5.23%$2,067
Year to date+17.30%+4.22%$1,173
1 year+15.13%+5.16%$1,151
3 years−16.82%+28.67%$832
5 years−28.40%+22.40%$716
10 years+135.44%+70.47%$2,354

Over the last 6 months it has done better than 98% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P/ASX 200: price only. Calculate your investment

The chart in detail

CSL: technical analysis

CSL is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 40.6% below its all-time closing high ($341.00, February 19, 2020).

Trend
Upward
RSI (14 sessions)
67
Between 30 and 70
vs 200-session average
+38.95%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

Support and resistance

Price areas where CSL has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$202.52
  3. Support$185.61−8.35%4 touches, last on October 1, 2026
  4. Support$176.00−13.10%5 touches, last on October 2, 2026
  5. Support$144.91−28.45%2 touches, last on April 8, 2026

Volatility and risk

Over the last year it has moved less than the S&P/ASX 200.

Beta (1 year) vs S&P/ASX 200
0.68
Volatility (60 sessions, annualised)
19.8%
Largest fall in the last year
−50.49%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

CSL: seasonality

Average monthly price change over 33 years

+0.9%Jan+2.0%Feb+0.2%Mar+1.3%Apr−0.3%May+2.5%Jun+2.3%Jul+4.5%Aug+0.3%Sep+0.8%Oct+3.3%Nov+2.8%Dec

Over the last 33 years, the strongest month for CSL has been August: +4.54% on average, positive in 22 years out of 33. The weakest has been May: −0.28% on average, positive in 19 years out of 32. November, the current month, has been positive in 22 years out of 32 (+3.29% on average).

Show chart data
MonthAverageMedianPositive years
January+0.89%+2.07%20 of 32
February+2.01%+2.19%17 of 32
March+0.24%+0.12%16 of 32
April+1.34%+2.30%22 of 32
May−0.28%+1.67%19 of 32
June+2.53%+0.87%18 of 33
July+2.30%+1.88%21 of 33
August+4.54%+2.91%22 of 33
September+0.33%+0.27%17 of 33
October+0.78%+0.20%17 of 33
November+3.29%+3.44%22 of 32
December+2.77%+2.80%21 of 32

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

CSL and its competitors

Known to many through its CSL Behring plasma products, CSL Seqirus influenza vaccines and CSL Vifor iron deficiency and nephrology treatments, the company researches, develops, manufactures and distributes biopharmaceutical products and vaccines. Its therapeutic areas include immunoglobulins, immunology, haematology, cardiovascular and renal conditions, and vaccines, with gene therapies and recombinant products also part of its portfolio. Sales reach customers in Australia, the United States, Germany, the United Kingdom, Switzerland, China and Hong Kong, as well as internationally.

Headquarters
Melbourne, Australia
Employees
29,000
Founded
1916
Chief executive
Gordon Naylor
CSL and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
CSLCSL$65.65B26.8%—+106.74%
Samsung Biologics207940$49.13B45.5%33.4+0.28%
Celltrion068270$36.68B31.6%26.4+19.29%
WuXi Biologics (Cayman)2269$24.52B32.4%35.1+38.78%
Innovent Biologics1801$18.84B7.4%111.5+2.32%
Sichuan Kelun-Biotech Biopharmaceutical6990$13.65B-0.2%—+0.78%

Same industry or related industries, similar size. Compare CSL with its competitors · Full profile